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Abstract Gastrointestinal stromal tumors (GISTs)
developing in the colon are rare, accounting for\5 % of all
GISTs. There are few data on the clinical efficacy of
tyrosine kinase inhibitors in colonic GISTs. We report here
on an 80-year-old male patient with advanced GIST of the
transverse colon. The patient underwent palliative resection
of the primary tumor because the disease was associated
with multiple liver metastases and peritoneal dissemina-
tion. Immunohistochemical analysis of the surgical speci-
mens showed KIT and CD34 expression. Sequence
analysis revealed that the tumor harbored deletion mutation
at codons 557–558 in exon 11 of the c-kit gene. A diagnosis
of colonic GIST was made. The patient postoperatively
underwent imatinib therapy for the remaining metastatic
tumors. Imatinib therapy induced a cyst-like appearance of
the liver metastases and stabilized the disease. In the
present case, c-kit gene analysis was found to be clinically
helpful for validating the diagnosis and therapeutic deci-
sion making for this rare disease.
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Introduction
Gastrointestinal stromal tumor (GIST) is an uncommon
disease, accounting for 0.1–3.0 % of all gastrointestinal
neoplasias [1, 2]. GISTs preferentially develop in the
stomach and the small bowel, although the tumors can arise
anywhere in the digestive tract from the esophagus to the
rectum. GISTs originating from the large bowel are rare,
accounting for only 5 % of all GISTs [3]. Colonic GIST is
even rarer because many of the large bowel GISTs arise in
the rectum. Owing to the lack of data on this rare malig-
nancy, the clinical and pathological features of colonic
GIST are still unclear.
Imatinib mesylate, a tyrosine kinase inhibitor, shows
high clinical efficacy in advanced GIST [4, 5] and is
now the standard treatment for unresectable and meta-
static GISTs [6]. However, data on the efficacy of
imatinib in colonic GIST are scarce only one report
written in Japanese is available [7]. The response to
imatinib is known to depend on the mutation sites of the
c-kit gene or the platelet-derived growth factor receptor-
alpha gene [8]. However, because data on the mutation
rate of the c-kit gene and the genotypic profile in colonic
GIST are also limited, it remains unknown whether or
not colonic GIST is as sensitive as stomach and small
bowel GISTs to imatinib.
We experienced a patient with advanced GIST of the
transverse colon. The patient underwent palliative
resection of the primary tumor and postoperative imati-
nib therapy. Here, we present the clinical course and our
analysis of data on c-kit gene mutation in the surgically
excised tumor.
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An 80-year-old man was diagnosed with a massive tumor
having a central ulceration in the transverse colon after
undergoing screening colonoscopy (Fig. 1). Computed
tomography (CT) revealed that the patient was suffering
from multiple metastases in the right hepatic lobe. Biopsy
specimens obtained by colonoscopy showed only necrotic
debris. Although confirmative diagnosis was not made, our
clinical diagnosis was colonic carcinoma associated with
multiple liver metastases. After obtaining the patient’s
informed consent, we planned surgical resection of both
primary colonic tumor and metastatic liver tumors.
Laparotomy revealed many whitish deposits that were
widely distributed in the peritoneal cavity. One of the
disseminated deposits was sent for pathological examina-
tion. A diagnosis of metastasis of sarcomatoid tumors was
made on the basis of histological examination using
intraoperative frozen section analysis. The patient under-
went only partial resection of the transverse colon to con-
firm the histological diagnosis of the tumor. The small
bowel was not involved in the colonic tumor. In addition,
no other tumors were found in the gastrointestinal tract.
The postoperative course was uneventful. The patient was
discharged on postoperative day (POD) 12.
Pathology and gene analysis
The colonic tumor measured 8.0 9 6.0 9 4.0 cm and
appeared as an exophytic growth with a deep central
ulceration that opened the colonic lumen (Fig. 2). Micro-
scopically, the tumor consisted of solid sheets of spindle
tumor cells with moderate atypia (Fig. 3a). Immunohisto-
chemical analysis revealed that the tumor cells were
positive for KIT (Fig. 3b) as well as CD34, and negative
for alpha-smooth muscle actin and S-100 protein expres-
sion. Based on these histological and immunohistochemi-
cal findings, the tumor was diagnosed as a GIST of the
transverse colon. The tumor showed markedly high mitotic
index, counting 11 in 10 high-power fields. The Ki-67
labeling index was 40 % (Fig. 3c). Lymph node metastasis
was also seen in a paracolic node that was surgically picked
up.
To make a confirmative diagnosis of GIST, we con-
ducted mutation analysis of the tumor. DNA was extracted
from the formalin-fixed, paraffin-embedded tumor tissues
and exons 9, 11, 13, and 17 of the c-kit gene were amplified
by the polymerase chain reaction. Sequence analysis
revealed that the tumor harbored deletion mutation at
codons 557–558 in exon 11 of the c-kit gene (Fig. 4). A
tumor that metastasized to the peritoneum showed the same
mutational genotype as the primary tumor.
Fig. 1 Colonoscopic finding. A large tumor having a central
ulceration was found in the transverse colon
Fig. 2 Macroscopic findings of the surgical specimen. a The tumor measured 8.0 9 6.0 9 4.0 cm and appeared as an exophytic growth (view
from the serosal side). b The tumor formed a deep central ulceration (view from the luminal side)
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Imatinib therapy
To control residual metastatic tumors, the patient was
started on imatinib therapy with a daily dose of 400 mg on
POD 39. A CT scan conducted 36 days after the start of
treatment revealed that all the metastatic tumors of the liver
showed a cyst-like appearance, indicating a significant
response to imatinib. Peritoneal metastases, which mea-
sured no less than 0.5 cm initially, became undetectable.
A CT scan performed 86 days after the treatment indicated
that the tumors shrank further with a 24 % reduction in size
(Fig. 5). The patient is continuing imatinib therapy and
living without disease progression so far.
Discussion
Clinicopathological data on colonic GIST patients are
scarce [9]. Only three case series studies concerning
colonic GIST are available so far [10–12]. We summarize
the results of these three case series studies of colonic
GIST in Table 1.
The first one is the study by Miettinen et al. [10]. They
analyzed the clinicopathological features of 37 cases of
colonic GISTs by reviewing the pathology files of the
Armed Forces Institute of Pathology and Helsinki Uni-
versity. The study by Miettinen et al. included a much
larger number of patients than the two other studies and
thus can be regarded as the basis for consideration of the
clinicopathological features of colonic GISTs. In their
series, the most common location of colonic GIST was the
sigmoid colon, followed by the transverse colon, the
cecum, the descending colon, and the ascending colon. The
sigmoid colon was also the most common site in a study by
Chen et al. [12]. However, in a study by Hassan et al [11],
three of four cases were found in the right-sided colon.
Shonaka et al. [13], by analyzing case reports of Japanese
patients with colonic GISTs, found that six of 14 cases of
colonic GIST developed in the sigmoid colon. Based on
these case series studies, we can understand that the sig-
moid colon is the most common site of colonic GISTs.
Fig. 4 DNA sequence analysis of the c-kit gene. Sequence analysis
revealed heterozygous deletion mutation (TGG AAG) at codons
557–578 in exon 11 of the c-kit gene. Nucleotide sequences and
corresponding codon numbers are indicated in the upper panel
Fig. 3 a The tumor consisted of solid sheets of spindle tumor cells
with moderate atypia (H&E stain, 9400). b The tumor cells diffusely
showed strong immunoreactivity for KIT (9400). c The Ki-67
labeling index was 40 % (9400)
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Concerning pathological features, the positive rates of
KIT expression in colonic GISTs ranged from 50-100 %
by immunohistochemical analysis. The tendency in
immunohistochemical features was not specified by the
previous studies. Meanwhile, as regards the malignant
potential of tumors, all the three studies showed high rates
of high-risk GIST, ranging from 43-75 %. A high
malignant potential may be one of the pathological features
of colonic GISTs. As a reflection of the high malignant
potential, the prognoses for colonic GIST patients seemed
to be poor overall. In Miettinen et al.’s study of the 28
patients who were followed up, 16 (57 %) died of the
Fig. 5 Contrast-enhanced computed tomography (CT) findings.
Liver metastases were transformed into sharply circumscribed, non-
enhanced homogeneous lesions 1 month after the start of imatinib
therapy. CT conducted 3 months after the start of imatinib therapy
showed that the response was still maintained. The upper panel shows
a metastasis located in the anterior segment of the liver (S5). The
lower panel shows a metastasis located in the posterior segment of the
liver (S6)
Table 1 Published case series studies of colonic GIST
C cecum, A ascending colon, T transverse colon, D descending colon, S sigmoid colon, MST median survival time, NA not analyzed
a Five of 14 tumors were analyzed
b All patients were still surviving at the median follow-up time of 27 months
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disease and the median survival time (MST) was
17 months. In the study by Hassan et al., three of four
patients died of GIST within 20 months and MST was
12 months. Meanwhile, no patient died of the disease in the
study by Chen et al. at the time of reporting, although the
median follow-up time was as short as 27 months. More
studies with long follow-up periods are needed to conclude
that colonic GIST is a GIST subset that is characterized by
poor prognosis.
The present case was positive for lymph node involve-
ment. Lymph node metastasis of GIST is rare. Dematteo
et al. [14] found lymph node metastasis in six (3 %) of 200
cases of GISTs of the digestive tract, and Miettinen et al.
[10] reported no lymph node metastasis in 37 cases of
colonic GISTs. In the present case, as the colonic tumor
was associated with peritoneal metastasis, lymph node
metastasis might be a reflection of the high grade malig-
nancy of this tumor.
Molecularly targeted therapy with imatinib mesylate is
the standard treatment for unresectable and metastatic
GISTs. Furthermore, imatinib therapy is now recom-
mended as postoperative adjuvant therapy for patients with
high-risk GISTs [15], as ample clinical evidence has been
accumulated [16, 17]. Thus, it is clinically important to
reveal whether or not imatinib is as clinically effective in
colonic GIST patients as in patients with stomach and
small bowel GISTs. Recently, a case series study addressed
the efficacy of imatinib against large bowel GISTs by
analyzing exclusively patients with rectal GISTs and not
including patients with colonic GISTs [18]. In that study,
of the 16 patients who underwent preoperative imatinib
therapy, 12 (75 %) showed partial response and the
remaining four, stable disease.
We searched published cases of colonic GIST patients
who underwent imatinib therapy using PubMed and
Japana Centra Revuo Medicina databases. The keywords
were ‘colon’, ‘GIST’, and ‘imatinib’. Hits were carefully
examined and only a single case report written in Jap-
anese was found to fit the prerequisites [7]. In that case
report, a 46-year-old male patient with KIT-positive
GIST of the ascending colon underwent postoperative
imatinib therapy because the circumferential tumor
margins were histologically positive. Despite ongoing
imatinib therapy, disseminated peritoneal metastases
appeared 9 months after the surgery and the patient died
of the disease 1 month later. In that case, the patient had
no target lesion and disease relapse occurred as early as
9 months after the surgery, making it difficult to evaluate
the effect of imatinib. In our case, the hepatic metastases
showed a significant response although it was evaluated
as stable disease on the basis of RECIST criteria.
Thus, the present case report is the first to indicate that
imatinib was effective for colonic GIST.
Gene analysis is important not only for the precise
diagnosis of GISTs but also for deciding the best treatment
strategy for GIST patients, because the effect of imatinib is
closely related to the mutation type of the c-kit gene in the
tumor. An exploratory study of patients enrolled in a phase
II study (B2222) [8] revealed that the response rates were
83.5 % in exon 11 mutations, 47.8 % in exon 9 mutations,
and 0 % in the wild type. These findings should underscore
the importance of adjuvant therapy in colonic GIST
patients because there are no reliable data on the clinical
efficacy of imatinib in these patients. Unfortunately,
genotype data are also scarce in colonic GIST. Miettinen
et al.’s study [10] was the only study that conducted c-kit
gene analysis. They reported c-kit mutations in five (36 %)
of 14 colonic GISTs. The genotypes were a point mutation
at codon 560 in two cases and a point mutation at codon
559, an in-frame deletion at codons 556–557, and an
in-frame deletion at codons 557–558 in one case each. In
the present case, an in-frame deletion mutation at codons
557–558 in exon 11 was found. These exon-11 mutations
in colonic GISTs are similar to those in stomach and small
bowel GISTs [19], suggesting that fundamentally similar
molecular alterations occur in colonic GIST.
In summary, we presented a case of a patient with a
transverse colon GIST. Mutation analysis showed an in-
frame deletion in exon 11 of the c-kit gene and confirmed
the diagnosis of colonic GIST. The patient underwent
imatinib therapy after palliative resection, and the treat-
ment yielded a significant response. This is the first report
demonstrating that imatinib was effective for the metastasis
of colonic GIST. There are a limited number of colonic
GIST patients in a single institution. To acquire funda-
mental clinical knowledge of colonic GIST, the accumu-
lation of case reports is essential.
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